TY - JOUR
T1 - Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin
AU - Moon, Chansoo
AU - Jung, Kyu Sik
AU - Kim, Do Young
AU - Baatarkhuu, Oidov
AU - Park, Jun Yong
AU - Kim, Beom Kyung
AU - Kim, Seung Up
AU - Ahn, Sang Hoon
AU - Han, Kwang Hyub
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2015/1/23
Y1 - 2015/1/23
N2 - Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients.Results: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).Conclusions: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.
AB - Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients.Results: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).Conclusions: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.
UR - http://www.scopus.com/inward/record.url?scp=84922072786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922072786&partnerID=8YFLogxK
U2 - 10.1007/s10620-014-3361-6
DO - 10.1007/s10620-014-3361-6
M3 - Article
C2 - 25236421
AN - SCOPUS:84922072786
SN - 0163-2116
VL - 60
SP - 573
EP - 581
JO - Digestive diseases and sciences
JF - Digestive diseases and sciences
IS - 2
ER -
